Dense Breasts, AI, and Extra Imaging: Three Questions Often Blended Together

Why you now get that letter

If your mammogram report mentioned breast density, that is not a new finding about you. It reflects a change in federal rules.

Under the Mammography Quality Standards Act, FDA now requires mammography facilities to tell patients about the density of their breasts. FDA reports that roughly half of women over 40 in the United States have dense breast tissue.

The letter is information, not an alarm. What it prompts, though, is a stream of news about AI, ultrasound, MRI, and more frequent screening. Those are not one recommendation.

This page explains federal sources. It is not medical advice and does not suggest a test or treatment.

What density actually is

NCI explains that breasts contain glandular tissue, fibrous connective tissue, and fatty tissue. Breast density describes the relative amount of each, as it appears on a mammogram. Dense breast tissue has more glandular and fibrous tissue and less fatty tissue.

Two points from NCI are worth holding onto. Dense tissue cannot be felt, not by you during a self-exam and not by a doctor during a clinical breast exam. Only a radiologist looking at a mammogram can tell. And density is reported using a four-category system called BI-RADS, so "dense" is not one single state.

NCI also notes that density changes with circumstances. Higher density is associated with using menopausal hormone therapy and with having a low body mass index. Lower density is associated with increasing age and with having children.

Why it matters for screening

FDA gives two reasons, and they are different from each other.

Dense breast tissue can make cancers harder to detect on a mammogram. NCI puts it more bluntly: mammography is more likely to miss cancer in women with dense breasts.

Separately, dense breasts have been identified as a risk factor for developing breast cancer at all.

One is a detection problem. The other is a risk problem. A story that merges them will point you toward the wrong question. Our page on what to ask after a density notice works through both.

Three separate decisions, often blended

When an AI headline lands on top of a density letter, it usually mixes these up:

1. Does software help read the mammogram itself? That is a question about image interpretation.
2. Does software estimate your risk, or select who should get more testing? That is a triage question, with different evidence behind it.
3. Should you have a supplemental test, such as ultrasound or MRI? That is a clinical decision about a whole additional examination.

A useful report says which of the three it is describing. Our comparison of mammogram, ultrasound, and breast MRI covers what each test does.

What supplemental screening evidence has to show

Finding more small tumors is not enough. A screening strategy has to be followed over more than one round, and researchers should report:

• interval cancers, meaning cancers that appear between scheduled screens
• how often people were called back when nothing was wrong
• how many biopsies resulted
• the stage at which cancers were found
• whether risk-based selection worked across different populations

FDA's own advice is measured. It recommends that patients with dense breasts talk to their health care provider about breast density, their risk for breast cancer, and their individual situation.

What density does not mean

• Dense breasts do not mean cancer is present.
• An AI analysis of a mammogram is not the same as a supplemental ultrasound or MRI.
• More testing finds more abnormalities, and it also produces more false positives and more biopsies.
• One density category does not set the same plan for everyone. Overall risk matters.

Mammography remains useful. How mammograms work explains what the test can and cannot show, including the callback process.

Questions after a density notice

• Which density category was reported for me?
• What is my overall breast cancer risk, taking everything into account?
• Would another test improve the benefit enough to justify the extra follow-up?
• If this center uses AI, what is it used for, and does a radiologist still read every exam?

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.